Lung fibrosis is a condition in which scar tissue builds up in the lungs, making them stiff and progressively harder to breathe with. The scarring replaces healthy, flexible lung tissue with thick, rigid material that prevents oxygen from passing efficiently into the bloodstream. In its most common form, idiopathic pulmonary fibrosis (IPF), median survival is 3 to 5 years from diagnosis, though the timeline varies widely depending on how early it’s caught and how the disease responds to treatment.
How Scarring Develops in the Lungs
Your lungs contain millions of tiny air sacs called alveoli. These thin-walled sacs are where oxygen moves from the air you breathe into your blood, and where carbon dioxide moves out. In lung fibrosis, the cells lining these air sacs become damaged. That damage triggers a wound-healing response, much like what happens when skin is cut. Cells called fibroblasts activate and begin producing structural material (collagen, elastin, and other proteins) to patch the injury.
The problem is that this repair process doesn’t shut off. Fibroblasts keep multiplying and producing structural material far beyond what’s needed. They also transform into a more aggressive cell type called myofibroblasts, which deposit even more scar tissue. Over time, the walls of the alveoli thicken and stiffen. What was once a delicate membrane thin enough for oxygen to cross becomes a rigid barrier. The lungs lose their ability to expand fully and can no longer move enough oxygen into the blood, eventually leading to respiratory failure in advanced cases.
Known Causes and Risk Factors
Lung fibrosis has many possible triggers, though in a large number of cases no cause is ever identified. When the cause is unknown, the condition is called idiopathic pulmonary fibrosis. Research estimates that roughly one in four IPF cases can be attributed to workplace dust and fiber exposure, even when a specific cause isn’t formally diagnosed.
Occupational and environmental exposures with strong links to lung fibrosis include:
- Asbestos: common in construction, shipyard, and insulation work
- Silica dust: found in mining, stone cutting, and sandblasting
- Metal dusts: nickel, iron, and aluminum particles found in manufacturing
- Wood dust and organic particles: linked to various interstitial lung changes
Beyond workplace exposures, lung fibrosis can also develop as a complication of autoimmune diseases (like rheumatoid arthritis or scleroderma), as a side effect of certain medications, or following radiation therapy to the chest. Smoking is an independent risk factor. The World Trade Center collapse in 2001 provided a stark example of environmental lung fibrosis: analysis of lung tissue from exposed individuals revealed silica, metals, carbon nanotubes, and asbestos fibers, and several cases of pulmonary fibrosis appeared within a decade.
What Lung Fibrosis Feels Like
The earliest and most common symptom is shortness of breath, particularly during physical activity. At first, you might notice it only when climbing stairs or exercising. Over months or years, it can progress to the point where even walking across a room feels difficult. A persistent dry cough that doesn’t produce mucus is the other hallmark symptom.
As the disease advances, oxygen levels in the blood drop. This can cause fatigue, lightheadedness, and a general feeling of being unwell. Some people develop clubbing, a visible widening and rounding of the fingertips and toenails that signals chronic low oxygen. These symptoms tend to creep in slowly, which is one reason lung fibrosis is often diagnosed later than it should be.
How It’s Diagnosed
High-resolution CT scanning (HRCT) of the chest is the primary tool for diagnosing lung fibrosis. Doctors look for a specific pattern called usual interstitial pneumonia, or UIP. A definite UIP diagnosis on imaging requires four features: scarring concentrated near the base and outer edges of the lungs, a net-like (reticular) pattern in the tissue, honeycombing (clusters of small cysts typically under 10 mm surrounded by visible walls), and the absence of features that would point to a different diagnosis.
Lung function tests complement the imaging. In fibrosis, the lungs can’t expand as much as they should, so total lung capacity drops below 80% of predicted values. A separate measurement called diffusion capacity, which tests how well oxygen crosses from the air sacs into the blood, also falls. Normal diffusion capacity is above 75% of predicted. A low score confirms that the scarring is actually interfering with gas exchange, not just showing up on a scan. In some cases where imaging and lung function tests aren’t conclusive, a tissue biopsy is needed. Current guidelines recognize a technique called transbronchial lung cryobiopsy as an acceptable alternative to surgical biopsy when performed at experienced centers.
Treatment Options
There is no cure for lung fibrosis, and existing scar tissue cannot be reversed. Treatment focuses on slowing the rate of new scarring and managing symptoms. Two antifibrotic medications are the cornerstone of therapy for IPF. Both work by interfering with the production and assembly of collagen fibers, the main structural protein in scar tissue. One of these drugs also reduces the production of other structural proteins like fibronectin that contribute to tissue stiffening. In lab studies, both medications slowed the formation of collagen fibers in a dose-dependent way.
These medications don’t stop the disease, but clinical trials have shown they reduce the rate at which lung function declines. Side effects, particularly gastrointestinal issues, are common and sometimes limit what patients can tolerate. Notably, current clinical guidelines recommend against using antacid medications or antireflux surgery as treatments for IPF itself, despite earlier theories that acid reflux might worsen fibrosis.
Supplemental oxygen becomes necessary for many people as the disease progresses, particularly during activity and sleep. Pulmonary rehabilitation, a structured program of exercise and breathing techniques, helps patients maintain function and quality of life even as lung capacity decreases.
Complications of Advanced Disease
As scar tissue accumulates, the blood vessels running through the lungs get compressed and damaged. This raises blood pressure in the arteries between the heart and lungs, a condition called pulmonary hypertension. About 40% of people with advanced pulmonary fibrosis develop this complication, and it significantly worsens both symptoms and survival. The combination of stiff lungs and high pulmonary pressure forces the right side of the heart to work much harder, which can eventually lead to right-sided heart failure.
Impaired gas exchange is the other major complication. Even at rest, the thickened alveolar walls may not allow enough oxygen to reach the blood, leading to chronically low oxygen levels that affect energy, cognition, and organ function throughout the body.
When Lung Transplant Becomes an Option
For people whose lung fibrosis continues to worsen despite treatment, lung transplantation is the only intervention that can meaningfully extend life. International guidelines recommend referral to a transplant center when lung function drops below 40% of predicted capacity, when oxygen supplementation becomes necessary, or when breathing difficulty and physical limitation are progressing despite medical therapy.
The general threshold for transplant candidacy is a greater than 50% risk of death within two years without a transplant, combined with a high likelihood of surviving the procedure and doing well afterward. Early referral is encouraged because the evaluation process and waiting period can take months to over a year, and patients need to be well enough to survive the surgery itself. Not everyone with advanced fibrosis qualifies, and the decision involves careful assessment of overall health, other medical conditions, and support systems.
Who Gets Lung Fibrosis
IPF is more common than many people realize. In the United States between 2017 and 2022, the adjusted prevalence was 34 to 67 per 100,000 people, with 10 to 18 new cases per 100,000 each year. The disease predominantly affects adults over 60, and men are diagnosed more often than women. There are also racial disparities: Black patients have higher rates of lung involvement when fibrosis develops alongside autoimmune disease and may have different survival outcomes compared to white patients. A family history of pulmonary fibrosis increases risk, and researchers have identified several genetic variants that make some people more susceptible to the disease even without obvious environmental triggers.